PubMed Trending Research Digest — October 20, 2026

Automated digest · 97 articles · 15 research areas · October 20, 2026

Overview

Across this week’s papers, a dominant theme is “systems-level” biology—linking molecular mechanisms to whole-organism outcomes using multi-omics, spatial profiling, and network-level readouts. In neuro-oncology and neurodegeneration, studies connect brain-network organization and immune/metabolic states (e.g., glioma functional connectivity indices; APOE4-driven neuroimmune loops; complement- and lipid-handling control of microglial pruning) to prognosis and potential therapeutic targets. In cancer, multiple groups converge on the idea that resistance and immune escape are not single-gene events but emergent properties of chromatin state, metabolism, and the tumor microenvironment (e.g., glutamine transporter vulnerabilities in PARPi resistance; exosome-driven epigenetic remodeling for liver metastasis; TEC “immune gatekeepers” and CAF signaling as barriers).

A second major thread is precision translation: better biomarkers, better patient stratification, and more tailored interventions. Large cohort and trial analyses emphasize risk prediction beyond conventional clinical variables—such as LOY as a hematopoietic aging biomarker for AMD, proteomics-derived risk scores for heart failure, and multi-omics predictors of measurable residual disease in hematologic malignancies. Clinical guidance and trial updates (advanced breast cancer consensus, ICU atrial fibrillation guidelines, PAH low-risk strategies, IBD treat-to-target STRIDE-III) reflect a field moving toward standardized, evidence-graded decision-making.

Finally, several studies highlight modifiable biological levers spanning inflammation, metabolism, and delivery technologies. Examples include microbiome–immune–metabolic pathways (gut-lung protection in ARDS; microbiota-derived bile acids for sex-specific liver protection), targeted immunomodulation in autoimmune disease (bispecific strategies for IBD; inflammasome activation via OCTN2–pyrin signaling), and engineering advances that expand therapeutic reach (extrahepatic LNP design; mechanobiology tools for 5-HT2A; improved imaging standardization for MS lesion assessment). Together, these works underscore a broad momentum toward combining mechanistic insight with scalable, clinically actionable tools.

---

Neuro-oncology & Brain Tumor Biomarkers

Intratumoral and Peritumoral Functional Connectivity Reveals Network-Level Signatures of Glioma.

This study used resting-state fMRI from 306 patients with pathologically confirmed glioma at two hospitals to characterize individualized intra- and peritumoral functional connectivity networks. It introduced two network indices—RIFR (ratio of intratumoral functional regions) and RPTR (ratio of peritumoral tumor-related regions)—and found that lower RIFR reflected diminished intratumoral connectivity and was associated with worse prognosis across pathological, structural, functional, cognitive, and language measures. These rs-fMRI network-level signatures may improve prognostic stratification and deepen understanding of glioma as a brain-network disease.

Bao H, Bai Y, Hu J et al. · MedComm · (2026) · View on PubMed ↗ · Free PDF ↗

Global variations, temporal trends, and socioeconomic inequalities in the burden of malignant brain and central nervous system tumors: a population-based systematic analysis of GLOBOCAN 2024.

This population-based systematic analysis estimated incidence, mortality, and lifetime risk of malignant brain and central nervous system tumors and quantified socioeconomic inequalities across countries using GLOBOCAN 2024, CI5plus, and World Population Prospects 2024. It reported global variations and temporal trends in disease burden, emphasizing lifetime risk and cross-country socioeconomic disparities rather than only incidence and mortality rates. The findings support more equitable, lifetime-risk–informed public health planning and resource allocation for malignant brain/CNS tumors.

Lei SY, Wu Y, Liu HJ et al. · Military Medical Research · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neuroimaging Methods & Diagnostic Criteria

Phase Image Display Settings for Paramagnetic Rim Lesion Detection in Multiple Sclerosis: A Practical Guide.

The article studied how phase-image window/level display settings affect detection of paramagnetic rim lesions (PRLs) on susceptibility-sensitive MRI sequences under the 2024 McDonald criteria framework in multiple sclerosis. It found that PRL visibility depends critically on workstation phase display conventions and that inappropriate phase windowing can render rims invisible, providing practical guidance to standardize PRL assessment across vendors. This improves the reliability of PRL-based diagnosis and progression monitoring in clinical and research MRI workflows.

Hagiwara A, Sonoda Y, Tomizawa Y et al. · Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurodegeneration & Neuroimmune Mechanisms (Alzheimer’s, HIV, Glaucoma, Epilepsy, ASD)

An acetylcholine-inhibited sleep-active hippocampal interneuron orchestrates memory consolidation.

This mouse study investigated how an acetylcholine-inhibited sleep-active hippocampal interneuron controls memory consolidation by gating hippocampal ripple generation during sleep. Using genetic targeting of M2 acetylcholine receptor (Chrm2)-expressing GABAergic interneurons, the authors identified a sparse interneuron population preferentially active during non-REM (NREM) sleep and quiet wakefulness that orchestrates ripple-dependent memory consolidation. The work is significant because it links a specific cholinergic receptor-defined interneuron circuit to the molecular-to-circuit mechanism of sleep-dependent memory.

Feng Y, Dai Q, Fei X et al. · Neuron · (2026) · View on PubMed ↗

Identification of platelet-derived biomarker in a cohort of Parkinson’s disease.

This study investigated whether platelet-derived signals can serve as biomarkers for Parkinson’s disease (PD) by analyzing substantia nigra (SN) microarray data and platelet RNA-seq data from newly recruited PD patients using weighted gene coexpression network analysis (WGCNA). It identified platelet-associated modules enriched for chromatin organization and DNA metabolism and screened candidate platelet biomarkers by differential comparisons. The results support the feasibility of using platelet RNA signatures as potential PD biomarkers and motivate validation in larger cohorts.

Dong ZY, Xiang Y, Wang L et al. · Genes & diseases · (2027) · 1 citations · View on PubMed ↗ · Free PDF ↗

OGT regulates RNA-binding protein nucleocytoplasmic partitioning, but this fails in amyotrophic lateral sclerosis.

This study investigated how O-linked N-acetylglucosamine transferase (OGT) regulates RNA-binding protein (RBP) nucleocytoplasmic partitioning in human-induced pluripotent stem cell–derived spinal motor neurons (hiPSC-MNs) as a model of amyotrophic lateral sclerosis (ALS). OGT-dependent control of RBP compartmentalization was found to fail in ALS-relevant conditions, implicating disrupted O-GlcNAc–linked regulation of RBP trafficking in disease mechanisms. These findings support OGT/RBP nucleocytoplasmic mislocalization as a mechanistic target for ALS therapeutic development.

Wang Y, Fournier L, Wymann B et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

SPRY1 suppresses microglial fatty acid oxidation by retaining FATP3 on the endoplasmic reticulum in Alzheimer’s disease.

This study investigated how SPRY1 regulates microglial lipid metabolism in Alzheimer’s disease using integrative transcriptomics of four human AD brain datasets, analyses of human post-mortem tissue, and functional validation in primary microglia, Drosophila, and APP/PS1-21 mice. The authors found that SPRY1 suppresses microglial fatty acid oxidation by retaining FATP3 on the endoplasmic reticulum, linking a specific lipid-handling mechanism to pathological microglial activation. These findings identify the SPRY1–FATP3 axis as a potential therapeutic target to modulate neuroinflammation in AD.

Zhang YG, Li SY, Hu YZ et al. · Journal of neuroinflammation · (2026) · View on PubMed ↗ · Free PDF ↗

Apolipoprotein E4 and immune dysfunction in Alzheimer’s disease: mechanisms and therapeutic implications.

This review examined how apolipoprotein E4 (APOE4) drives immune dysfunction in Alzheimer’s disease by coordinating central microglial states with peripheral immune remodeling. It concludes that APOE4 shifts microglia away from homeostatic surveillance toward metabolically stressed, inflammatory, synaptotoxic phenotypes and primes peripheral innate/adaptive immune cells toward pro-inflammatory responses, forming a self-reinforcing neuroimmune loop that accelerates neurodegeneration. The mechanistic synthesis highlights APOE4-linked immune pathways as therapeutic targets to slow Alzheimer’s progression.

Shi H, Zhao Y, Zhu W et al. · Trends in neurosciences · (2026) · View on PubMed ↗

Ginsenoside Compound K Inhibits Complement C1qA/C3-CR3-Mediated Microglial Synaptic Pruning and Neuronal Pyroptosis.

The study investigated whether ginsenoside compound K (CK) can inhibit complement C1qA/C3–CR3-mediated microglial synaptic pruning and neuronal pyroptosis in an Alzheimer’s disease model. In APP/PS1 mice treated with CK (20 or 40 mg/kg/day), CK reduced aberrant microglial synaptic phagocytosis and neuronal pyroptosis by suppressing the complement C1qA cascade, with memantine used as a comparator. This supports CK as a candidate neuroprotective agent targeting complement-driven neuroinflammation and pyroptotic cell death.

Zhao X, Liu J, Wang S et al. · Journal of ethnopharmacology · (2026) · View on PubMed ↗

AKAP1 Protects Retinal Ganglion Cells and Preserves Vision by Improving Mitochondrial and Synaptic Health in Glaucomatous Neurodegeneration.

This study investigated the mitochondrial scaffold protein A-kinase anchoring protein 1 (AKAP1) in glaucomatous neurodegeneration, using glaucomatous retina analyses and AAV2-mediated approaches to assess retinal ganglion cell (RGC) survival and function. It found that AKAP1 is reduced in glaucomatous retinas and that restoring AKAP1 improves mitochondrial dynamics, reduces oxidative stress, preserves synaptic health, and protects vision. The results support AKAP1 as a neuroprotective target for glaucoma by linking intraocular pressure–associated stress to mitochondrial and synaptic failure.

Bastola T, Kim KY, Shen Z et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Astrocyte-Associated ABCA1/APOE Responses Accompany Hippocampal Lipid Remodeling and Ectopic Neuronal Accumulation During Epileptogenesis.

This study analyzed human temporal lobe epilepsy (TLE) and kainic acid (KA)-treated mouse transcriptomic datasets to define astrocyte-linked lipid responses during epileptogenesis, focusing on ABCA1 and APOE. It found that astrocyte-associated ABCA1/Abca1 and ABCA1/APOE responses accompany hippocampal lipid remodeling and correlate with ectopic accumulation of granule cells and immature neurons in the hilus. The work links astrocyte lipid transporter/apolipoprotein signaling to structural neuronal misplacement during epileptogenesis, highlighting potential lipid-targetable mechanisms in TLE.

Chen L, Shi XR, Chen JY et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Thioredoxin-2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation.

This study examined how mitochondrial thioredoxin-2 (TRX2) regulates osteoporotic bone loss in endothelial cells, focusing on aging bone vascular endothelial cells and FOXO3a signaling. Endothelial Trx2 deficiency accelerated skeletal degeneration by suppressing osteogenic activity and enhancing osteoclastogenesis, and TRX2 directly bound FOXO3a via a redox-sensitive Cys90–Cys31 disulfide interaction to retain FOXO3a at the mitochondrial outer membrane. These findings identify TRX2–FOXO3a redox control as a mechanistic target to prevent endothelial dysfunction–driven osteoporosis.

Zhan C, Zhou Z, Ding Y et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

PBRM1 Deficiency in Microglia Leads to Excessive Neurogenesis and Autism-Like Behaviors via the CCL5-CCR1/5-β-catenin Signaling Axis.

This study investigated whether microglial loss of the autism risk gene PBRM1 (Polybromo 1) drives neurodevelopmental phenotypes via CCL5-CCR1/5–β-catenin signaling in mice. Microglial PBRM1 deficiency altered microglial clusters, increased neurogenesis, and produced autism-like behaviors, with mechanistic data showing PBRM1 directly represses the Ccl5 promoter and thereby modulates downstream CCR1/5–β-catenin pathway activity. These results implicate microglial PBRM1–CCL5 axis dysregulation as a causal pathway for ASD-like behaviors and a potential therapeutic target.

Duan YY, Jiao LF, Liu PP et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Molecular Signatures of HIV-Induced Neuroinflammation and Neurodegeneration in Human Cerebral Organoids: Identification of Therapeutic Targets for NeuroHIV.

This study used HIV-1-infected human cerebral organoids containing microglia and validated findings in cART-treated SIV-infected rhesus macaques to map molecular signatures of HIV-induced neuroinflammation and neurodegeneration. Using integrated single-nucleus RNA sequencing with ATAC-seq (multi-omics), the authors identified cell-type-specific inflammatory and degenerative programs and proposed therapeutic targets for NeuroHIV. Scientifically, it provides a translational atlas linking chromatin accessibility and gene expression changes to candidate interventions in HIV-associated CNS disease despite viral suppression.

Chennakesavan K, Samikkannu M, Gupta S et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

The impact of creatine on brain functions.

This review synthesized evidence on how creatine supplementation and brain creatine homeostasis affect central nervous system (CNS) functions, including constraints imposed by the blood–brain barrier and differences between brain and muscle uptake. The key conclusion is that creatine can increase brain intracellular concentrations but the magnitude is limited and effective CNS-targeted dosing strategies remain under development. Scientifically, it frames creatine as a bioenergetic modulator with potential relevance to neuropsychiatric and neurological function, while highlighting dosing and delivery as major research gaps.

Borowski T, Zimoń M, Piegza MJ · Psychiatria polska · (2026) · View on PubMed ↗ · Free PDF ↗

Differential evolution of neuroinflammatory remodeling programs related to scar formation and regeneration in spinal cord injury: A cross-species multi-omics analysis.

This cross-species multi-omics analysis compared neuroinflammatory remodeling programs after spinal cord injury in mammals (mouse) versus regenerative repair in zebrafish using single-cell/single-nucleus transcriptomics, spatial transcriptomics, chromatin accessibility profiling, and computational pathway/regulon modeling. The key finding was that injury-induced inflammatory and scar-associated remodeling programs evolve differently across species, with zebrafish attenuating inflammatory programs relative to mammals. This work is significant because it identifies molecular regulators distinguishing scar-forming versus regeneration-permissive responses, informing targets to improve spinal cord repair.

Tang H, Cheng F, Xu J et al. · Neural regeneration research · (2026) · View on PubMed ↗ · Free PDF ↗

---

Psychiatric Effects of Substances & Sleep

Acute Psychosis and Dissociative Syndrome Following Binge Recreational Nitrous Oxide Use: A Case Report.

This case report describes an early-20s woman with no prior psychotic history who developed an acute psychotic and dissociative syndrome after binge recreational nitrous oxide (N2O) use at an outdoor music festival, with concurrent exposure to 3,4-methylenedioxymethamphetamine (MDMA) and sleep deprivation. Her symptoms emerged over three days and included profound disorientation, delusions, passivity phenomena, and auditory/olfactory hallucinations. The report highlights a clinically important association between acute N2O binge exposure (especially with other substances and sleep loss) and severe transient psychiatric syndromes.

Agostinho F, Moutinho A, Câmara CK et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Immunotherapy & Tumor Microenvironment (CAR-T, NK, Vascular/CAF, Immuno-exclusion)

Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy.

This study analyzed pre-treatment bone marrow transcriptomics and genetic alterations in 15 relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) patients enrolled in a phase II trial of CD19 CAR T-cell therapy, stratified into 8 good responders and 7 poor responders at a 3-month landmark. Patients with poor response showed a myeloid-like transcriptomic signature prior to CAR T-cell treatment. The results suggest that baseline leukemia-intrinsic RNA programs may predict CD19 CAR T-cell efficacy and could inform patient selection or combination strategies.

Wang S, Liu W, Wang Y et al. · Cancer medicine · (2026) · View on PubMed ↗

NK cell immune fitness stratifies small cell lung cancer into four functional states associated with clinical response.

This study profiled circulating natural killer (NK) cells in patients with small-cell lung cancer (SCLC) at baseline and after cisplatin treatment, stratifying participants by clinical response using transcriptomics, cytokine profiling, and high-dimensional functional assays. NK-cell immune “fitness” patterns defined four functional states that were associated with clinical response to chemotherapy and immunotherapy. These findings support NK-cell functional state profiling as a potential biomarker strategy to predict and stratify treatment benefit in SCLC.

De Rosa C, Somma F, Amato L et al. · The journal of liquid biopsy · (2026) · View on PubMed ↗ · Free PDF ↗

Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells.

This preclinical study investigated how glioblastoma (GB) immune landscapes change after treatment with CD70-targeted CAR-T cells in murine models. Using bulk RNA sequencing and related analyses after CD70-target interception, the authors characterized immune landscape remodeling following mCD70-directed CAR-T therapy that had previously shown durable remission in orthotopic syngeneic GB. The work is significant because it links CD70 CAR-T activity to post-treatment tumor microenvironment changes that may explain efficacy limits and inform next-generation GB immunotherapies.

Kourtesakis A, Agardy DA, Tejido Dierssen C et al. · Oncoimmunology · (2026) · View on PubMed ↗ · Free PDF ↗

Evolution of CAR-T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies.

This review summarized advances in CAR-T therapy across functional engineering, manufacturing innovation, alternative cell sources, and future in vivo CAR programming. It highlights how engineering strategies (e.g., cytokine-armoring and checkpoint resistance) and manufacturing improvements aim to address limitations such as autologous production complexity, cost, scalability, variable product quality, reduced solid-tumor efficacy, and treatment-related toxicities. The article is significant because it provides a roadmap for next-generation CAR-T designs intended to improve efficacy and broaden clinical applicability.

Sakoda Y · Cancer science · (2026) · View on PubMed ↗ · Free PDF ↗

Tumor endothelial cells as vascular immune gatekeepers: reprogramming the vascular-immune interface for cancer immunotherapy.

The article studied tumor endothelial cells (TECs) as “vascular immune gatekeepers” that regulate immune cell trafficking and function in solid tumors, focusing on mechanisms that create immune-excluded tumor microenvironments. It found that pro-angiogenic signaling and metabolic stress drive TECs to form multilayered immune barriers via abnormal, poorly perfused vasculature, endothelial anergy, and immunosuppressive programs that directly suppress effector T cells and NK cells. This provides a rationale for reprogramming the vascular–immune interface to improve the efficacy of cancer immunotherapy in refractory solid tumors.

Zhang T, Zhang C, Wang C et al. · Cancer letters · (2026) · View on PubMed ↗

Targeting Cancer-Associated Fibroblasts with Small-Molecule Inhibitors: Molecular Mechanisms and Therapeutic Potential.

This review examined small-molecule strategies to target cancer-associated fibroblasts (CAFs) in the tumor microenvironment and summarized their molecular mechanisms and therapeutic potential. It highlights that CAF activation and pathogenic functions are sustained by signaling axes including TGF-β/STAT3, NF-κB, Notch, Hedgehog, PI3K/AKT, and CXCL12/CXCR4, and it emphasizes mechanistic diversity and translational barriers for small-molecule stromal modulation. The review is clinically relevant because it consolidates actionable pathways for developing next-generation CAF-targeting drugs.

Liu Q, Huo Z, Zhou M et al. · Drug design, development and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Delayed elective nodal irradiation in head-and-neck cancer radiotherapy reduces acute lymphocyte damage, lymphopenia, and modulates immune signatures.

This randomized clinical study in 28 patients with locally advanced head-and-neck squamous cell carcinoma compared standard elective nodal irradiation (ENI) versus delayed ENI (upfront boost to gross disease/involved nodes followed by standard ENI) to reduce radiation-induced lymphocyte damage. Delayed ENI reduced radiation-induced lymphocyte DNA damage and lymphopenia and modulated peripheral immune signaling compared with standard ENI. The findings are significant for preserving immune function to potentially improve radiotherapy–immunotherapy synergy in head-and-neck cancer.

Kaufmann J, Salah A, Marini F et al. · Clinical and translational radiation oncology · (2027) · View on PubMed ↗ · Free PDF ↗

---

Cancer Epigenetics & Chromatin Architecture

Targeting oncogenic SOX2 condensates suppresses squamous cell carcinoma progression.

This study investigated whether targeting SOX2 phase-separated condensates could suppress squamous cell carcinoma (SCC) progression across esophageal, head and neck, and lung SCCs. Using site-specific mutagenesis, orthotopic mouse models, and multi-omics sequencing, it showed that SOX2 activation domain 1 (AD1) promotes condensate formation and that SOX2 condensates enhance chromatin occupancy and H3K27ac at oncogenic loci such as FGFR2, driving tumor progression. The work is significant because it identifies SOX2 condensates as a potentially druggable cancer hallmark and links condensate biology to actionable oncogenic transcriptional programs.

Luan S, Sun J, Dong Y et al. · Cell reports. Medicine · (2026) · View on PubMed ↗

Epigenetics in development, disease, and therapy: from mechanisms to clinical interventions.

This review article synthesized evidence on epigenetic mechanisms—including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs—and how they drive development, disease, and aging. It highlights how epigenetic dysregulation contributes to cellular differentiation, tissue homeostasis, and therapeutic opportunities, and it surveys emerging clinical interventions targeting epigenetic regulators. The significance is that it frames actionable mechanistic targets and therapeutic directions for translating epigenetic biology into treatments.

Ren Y, Yang L, Fei B et al. · Science China. Life sciences · (2026) · View on PubMed ↗

Emerging Lipid Nanoparticle Targeting Strategies for Extrahepatic Delivery of RNA Therapeutics.

This review examined emerging lipid nanoparticle (LNP) targeting strategies aimed at improving extrahepatic delivery of RNA therapeutics beyond the liver. It focuses on engineering approaches such as lipid chemistry changes, particle engineering, surface functionalization, protein corona modulation, and route-specific administration to overcome conventional LNP hepatotropism and improve delivery to tissues including spleen, lungs, lymph nodes, brain, and tumors. The scientific significance is that it consolidates design principles for expanding RNA therapeutics to non-hepatic targets with better tissue specificity and delivery efficiency.

Li J, Liu J, Wang N et al. · Advanced materials (Deerfield Beach, Fla.) · (2026) · View on PubMed ↗

New perspective on epigenetic modification and immunotherapy in endometrial cancer.

This review examined epigenetic dysregulation in endometrial carcinoma (EC), focusing on DNA methylation regulators, histone-modifying enzymes, and epigenetic targets across EC molecular subtypes including POLE-mutated and mismatch repair-deficient tumors. It highlights aberrant DNA methylation, histone methylation/acetylation, and chromatin remodeling as drivers of immune evasion and therapeutic resistance, emphasizing druggable targets such as DNMTs, HDACs, LSD1, EZH2, PRMTs, and BET proteins. The synthesis supports epigenetic therapies and immunotherapy combinations as a rational strategy for improving outcomes in EC.

Zhang H, Shen D, Lin N et al. · Clinical epigenetics · (2026) · View on PubMed ↗ · Free PDF ↗

Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study.

This multicenter, single-arm phase 2 trial evaluated ifupinostat (BEBT-908), a dual HDAC and PI3Kα inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least two prior systemic therapies. Participants received intravenous ifupinostat on a defined 21-day schedule, and the primary endpoint was objective response rate (ORR) assessed by blinded independent central review. The study’s clinical significance lies in determining whether this epigenetic–PI3Kα targeted approach can produce meaningful responses and acceptable safety in heavily pretreated DLBCL.

Shi Y, Liu P, Li Y et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Metabolism & Targetable Vulnerabilities

Endothelial exosomes remodel chromatin accessibility and superenhancer in cancer cells to promote liver metastatic colonization.

This study tested whether endothelial exosomes remodel chromatin accessibility and superenhancers in cancer cells to promote liver metastatic colonization, focusing on liver-organotropic metastasis models such as uveal melanoma and pancreatic ductal adenocarcinoma. The authors found that exosome-driven chromatin and superenhancer remodeling enhances colonization-associated phenotypes (including proliferation, survival, cancer stem cell traits, and motility) by activating transcription programs linked to superenhancer-associated genes. This mechanistic insight suggests that disrupting exosome-mediated epigenetic remodeling could be a strategy to prevent or treat liver metastases.

Jin B, Liu S, Huang H et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer.

The study examined whether targeting SLC1A5-mediated glutamine metabolism could overcome PARP inhibitor (PARPi) resistance in ovarian cancer cells and in vivo models. In PARPi-resistant ovarian cancer, glutamine transporter SLC1A5 was upregulated and SLC1A5 inhibition increased sensitivity to olaparib, with USP14 stabilizing SLC1A5 by removing K48-linked polyubiquitin chains to enhance glutamine uptake and glutathione synthesis. This identifies a USP14–SLC1A5 metabolic vulnerability as a potential therapeutic strategy to reverse olaparib resistance in ovarian cancer.

Han F, Du H, Tian K et al. · Cell death & disease · (2026) · View on PubMed ↗ · Free PDF ↗

Tubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting PLK1 to Impair CEP55-ESCRT-Associated Vesicular Damage Clearance.

This preclinical cancer study investigated Tubocapsenolide A (TA) in oxaliplatin-resistant colorectal cancer (CRC) models and identified its molecular target using a PROTAC-based target deconvolution strategy. It found that TA directly targets PLK1, suppressing CRC growth and sensitizing oxaliplatin-resistant tumors by impairing CEP55-ESCRT-associated vesicular damage clearance via CEP55 Ser436 phosphorylation. Clinically, targeting the PLK1–CEP55–ESCRT axis may overcome oxaliplatin resistance in CRC.

Yang Y, Liang J, Wang L et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemia.

This study investigated how pitavastatin affects venetoclax resistance mechanisms in acute myeloid leukemia, with emphasis on TP53-mutant disease and other resistance pathways such as FLT3 mutation, MCL-1 upregulation, and mitochondrial metabolic changes. Pitavastatin counteracted multiple venetoclax resistance mechanisms, including resistance associated with TP53 mutation. The work suggests a potential pharmacologic strategy to restore venetoclax sensitivity in AML patients with high-risk genetic and metabolic resistance features.

Buono R, Juarez D, Paul M et al. · Blood neoplasia · (2026) · View on PubMed ↗ · Free PDF ↗

---

Precision Oncology & Clinical Trials (Solid Tumors, Hematologic Malignancies, Risk Stratification)

Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.

This study profiled 423 tumor samples from patients with newly diagnosed multiple myeloma (NDMM) in the MIDAS cohort to identify genomic, transcriptomic, and epigenomic predictors of measurable residual disease (MRD) after quadruplet induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd). Postinduction MRD-negativity varied across molecularly heterogeneous tumor states, and integrated multi-omics features were used to characterize which molecular programs were associated with MRD outcomes. These findings could enable earlier, biology-driven risk stratification to guide treatment intensification or de-escalation in NDMM receiving Isa-KRd.

Magrangeas F, Cherkaoui M, Bessonneau-Gaborit V et al. · Nature medicine · (2026) · View on PubMed ↗

Individualized Cardiac Index-Guided Hemodynamic Therapy in High-Risk Patients Undergoing Elective Major Abdominal Surgery: The PELICAN Randomized Clinical Trial.

This multicenter randomized clinical trial studied whether individualized cardiac index–guided intraoperative hemodynamic therapy improves outcomes in high-risk patients undergoing elective major abdominal surgery. Compared with routine hemodynamic therapy, the cardiac index–guided strategy was tested for superiority in reducing adverse outcomes in the trial population across 12 university centers in Austria, the Czech Republic, Denmark, Germany, and Spain. If effective, cardiac index–guided management could refine perioperative hemodynamic protocols to improve safety in high-risk surgical patients.

Saugel B, Meidert AS, Meyhoff CS et al. · JAMA · (2026) · View on PubMed ↗

Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune Microenvironments.

This study used whole exome sequencing, spatial transcriptomics, and spatial proteomics to compare pancreatic ductal adenocarcinoma (PDAC) tumor subtypes and immune microenvironments between Black African American (BAA) and Non-African American (NAA) patients. The authors found race-associated differences in tumor programs and immune niches, while exome sequencing showed no significant differences in driver mutations between groups. These findings suggest that spatially resolved molecular phenotypes—not driver mutation identity—may underlie disparities and could inform more tailored PDAC biology and therapies.

Wu Y, Sålas-Escabillas DJ, Xie A et al. · Cancer research · (2026) · View on PubMed ↗

Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial.

This phase III noninferiority randomized trial compared hypofractionated postmastectomy radiotherapy (42.56 Gy in 16 fractions) versus conventional fractionation (50 Gy in 25 fractions) in high-risk operable breast cancer patients receiving postmastectomy radiotherapy with internal mammary node irradiation (IMNI). The key finding was the trial’s assessment of whether the hypofractionated regimen achieved noninferior efficacy and acceptable safety relative to the conventional regimen while targeting internal mammary nodes. If noninferiority is confirmed, HypoMast-IMNI would support shorter-course IMNI-containing PMRT as a clinically practical standard for high-risk patients.

Wang X, Zhang X, Chen X et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Huntington’s disease clinical trials update: August 2026.

This article is a clinical trials update summarizing major developments in Huntington’s disease therapeutics as of August 2026. It reports on the launch and discontinuation of the first-in-human phase I study POINT-HD of RG6496 (an allele-selective antisense oligonucleotide targeting mutant huntingtin), and it highlights ongoing phase III efficacy trials including INVEST-HD (votoplam) and PRECISE-HD (pridopidine). The significance is that it consolidates current evidence and trial status to guide researchers and clinicians on the evolving HD therapeutic pipeline.

Farag M, Kinyomi O, Tabrizi SJ et al. · Journal of Huntington’s disease · (2026) · View on PubMed ↗ · Free PDF ↗

Clinical Outcomes of Sequential Cabozantinib and Axitinib After First-Line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma: A Single-Center Exploratory Study.

This single-center exploratory retrospective study assessed clinical outcomes in 12 patients with advanced renal cell carcinoma (RCC) who received sequential cabozantinib and axitinib after first-line nivolumab plus ipilimumab. The analysis evaluated outcomes by treatment order and by early progressive disease status after immunotherapy. The findings inform real-world sequencing considerations for VEGFR tyrosine kinase inhibitors following checkpoint inhibitor combination therapy in advanced RCC.

Furubayashi N, Kojima T, Nakano Y et al. · Research and reports in urology · (2026) · View on PubMed ↗ · Free PDF ↗

Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice.

This review summarized how oncogenic mutations in non-small cell lung cancer (NSCLC) translate from molecular mechanisms to clinical practice, with emphasis on targeted therapies including next-generation tyrosine kinase inhibitors (TKIs) and targeted antibodies. It highlights key clinical challenges such as selecting individualized agents, managing TKI resistance, and addressing CNS progression despite improved blood–brain barrier penetration. The synthesis frames mutation-driven precision treatment while underscoring the need for strategies that overcome resistance and prevent or treat brain metastases.

Li C, Yin X, Zhou S et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Subtype- and functional class-dependent prognostic impact of CSF3R mutations in acute myeloid leukaemia: A cohort study of 2500 patients.

The study analyzed prognostic effects of CSF3R mutations across molecular subtypes and functional classes in 2500 newly diagnosed de novo non-acute promyelocytic leukemia (non-APL) acute myeloid leukemia patients treated with intensive induction therapy. CSF3R mutations (3.5%) frequently co-occurred with CEBPA-bZIP mutations and RUNX1::RUNX1T1 fusions and were associated with inferior relapse-free survival (RFS) but not overall survival (OS) or event-free survival (EFS). This clarifies that CSF3R mutation status is a relapse-risk biomarker in AML and supports more refined risk stratification by mutation context.

An J, Hui Y, Li Y et al. · British journal of haematology · (2026) · View on PubMed ↗ · Free PDF ↗

8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines).

The guideline update studied evidence-based recommendations for managing advanced breast cancer (inoperable locally advanced or metastatic) across all subtypes, based on the ABC8 international consensus conference. It provides updated clinical guidance for healthcare professionals and patients using best available evidence and expert consensus where evidence is limited. This supports standardized, up-to-date care decisions for patients with advanced breast cancer worldwide.

Cardoso F, Ribeiro JM, Schumacher-Wulf E et al. · Breast (Edinburgh, Scotland) · (2026) · View on PubMed ↗ · Free PDF ↗

Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study.

This study analyzed survival outcomes in advanced non-small cell lung cancer (NSCLC) patients from the LC-SCRUM-Asia cohort (Taiwanese and Japanese patients) using a tiered grouping of disease-driven oncogenes based on NGS results and the number of approved targeted therapy lines in Taiwan and Japan. The key finding was that overall survival differed across oncogene tiers, with the tiered oncogene framework showing prognostic stratification in the Taiwanese cohort and validation in 8,619 Japanese patients. This is significant for precision oncology because it provides a practical, therapy-line–informed method to predict outcomes and guide targeted treatment decisions across populations.

Kuo CS, Umemura S, Wang CC et al. · Lung Cancer (Auckland, N.Z.) · (2026) · View on PubMed ↗ · Free PDF ↗

Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis.

This multicenter retrospective CUBIC consortium study evaluated real-world outcomes of the CD20×CD3 bispecific antibody mosunetuzumab in 119 patients with relapsed/refractory non-Hodgkin lymphoma, including a large subgroup with indolent lymphomas and poor performance status/comorbidities. Mosunetuzumab produced an overall response rate of 87% (with 97% receiving single-agent mosun), supporting effectiveness in patients who would often be ineligible for the registrational trial. These findings strengthen the clinical evidence base for mosunetuzumab use in frailer real-world indolent lymphoma populations where trial data are limited.

Jallouk AP, Falchi L, Chauhan A et al. · Blood neoplasia · (2026) · View on PubMed ↗ · Free PDF ↗

Cannabidiol (CBD) for Pain: A Narrative Review of Evidence to Date.

This narrative review synthesized preclinical mechanistic data, pharmacokinetics, and clinical trial evidence on cannabidiol (CBD) for pain across major pain conditions in humans. Overall, the review summarizes the current state of evidence for and against CBD analgesic efficacy and safety, noting that CBD’s regulatory status as an analgesic remains unapproved. Clinically, it helps frame where CBD may be promising versus where evidence gaps and safety/quality considerations limit routine adoption.

Raffa RB, Pergolizzi JV, Breve F et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Rethinking the Platinum Standard in SCLC: A Meta-Analysis of Limited- and Extensive-Stage Disease in the Immunotherapy Era.

This systematic review and meta-analysis evaluated first-line chemoimmunotherapy in small-cell lung cancer (SCLC) in the immunotherapy era, comparing cisplatin versus carboplatin platinum backbones across limited- and extensive-stage disease. The key finding was the impact of platinum backbone selection on survival outcomes when combined with immunotherapy, stratified by disease stage. Clinically, it informs optimization of the “platinum standard” in SCLC by clarifying whether cisplatin or carboplatin better supports survival in modern treatment regimens.

Meirson T, Ditzian Kugler H, Hanovich E et al. · JTO clinical and research reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Infectious Disease, Vaccines & ICU Antimicrobial Stewardship

Efficacy, Effectiveness, and Immunogenicity of the Respiratory Syncytial Virus Prefusion F Vaccine Administered During Pregnancy: Protocol for a Living Systematic Review and Meta-Analysis.

This living systematic review and meta-analysis protocol studies the efficacy, effectiveness, and immunogenicity of the respiratory syncytial virus (RSV) prefusion F vaccine administered during pregnancy, focusing on maternal immunization with the bivalent RSV-A/RVS-B prefusion F protein subunit vaccine (ABRYSVO). It aims to synthesize post-licensure real-world evidence across settings and seasons, including antibody durability and transplacental antibody transfer, building on the MATISSE pivotal trial. The protocol is significant because it will guide evidence-based recommendations for RSVPreF use in pregnancy by quantifying benefits and immune correlates in infants.

Mazzoni A, Bardach A, Berrueta M et al. · JMIR research protocols · (2026) · View on PubMed ↗ · Free PDF ↗

Incidence and mortality of invasive fungal infections among patients admitted in intensive care units in India: findings from a multicentric registry-based study (2023-25).

This multicentric registry-based observational study characterized invasive fungal infections among ICU patients in India using data from 63 ICUs across eight advanced mycology diagnostic centers (Jan 2023–Nov 2025). It assessed IFI incidence, risk factors, resistance patterns, treatment, and outcomes in proven/probable cases defined by EORTC/MSG criteria. The results are significant for improving ICU antifungal stewardship and guiding empiric/targeted management in a high-burden setting.

Goyal SP, Sharma S, Kaur H et al. · The Lancet regional health. Southeast Asia · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardiovascular Disease & Hemodynamic/Thrombotic Risk

Large-scale plasma proteomic profiling enhances prediction of heart failure among hypertensive individuals: prospective insights from the UK Biobank.

This prospective UK Biobank analysis studied whether large-scale plasma proteomic profiling improves prediction of incident heart failure among hypertensive individuals without baseline heart failure. Using Olink Explore measurements of 2,911 proteins and Cox modeling with LASSO to build a protein risk score (PRS), the authors enhanced HF risk stratification beyond conventional approaches. Clinically, a proteomics-derived PRS could enable earlier identification of hypertensive patients at highest risk for heart failure.

Li M, He X, Xiao S et al. · Journal of global health · (2026) · View on PubMed ↗ · Free PDF ↗

Guidelines for the management of atrial fibrillation in adult patients admitted to an intensive care unit.

This article developed French Intensive Care Society guidelines for atrial fibrillation management in adult intensive care unit (ICU) patients using the GRADE methodology. It addressed 24 clinical questions, with 21 focused on specific management aspects relevant to ICU populations. These recommendations provide standardized, evidence-graded decision support for treating ICU-associated atrial fibrillation where cardiology-derived guidance may not fully apply.

Labbé V, Aissaoui N, Asfar P et al. · Annals of intensive care · (2026) · View on PubMed ↗ · Free PDF ↗

Myosin inhibitor therapy in Fabry cardiomyopathy with dynamic left ventricular outflow obstruction.

This case report studied a 56-year-old woman with Fabry disease (GLA p.Glu358del) and a concomitant PLN variant who had dynamic left ventricular outflow tract (LVOT) obstruction despite enzyme replacement therapy and optimized medical treatment. Treatment with the cardiac myosin inhibitor mavacamten led to a marked reduction in LVOT gradient and improved functional status from NYHA class III to class I within three months. The case highlights the value of detailed genetic/phenotypic characterization in Fabry cardiomyopathy and suggests myosin inhibition as a potential targeted therapy for dynamic LVOT obstruction.

Lau K, Petri N, Nordbeck P · American heart journal plus : cardiology research and practice · (2026) · View on PubMed ↗ · Free PDF ↗

Pre-stroke functional status and prognosis following mechanical thrombectomy: Systematic review and meta-analysis.

This systematic review and meta-analysis studied how pre-stroke functional status affects prognosis after mechanical thrombectomy (MT) for ischemic stroke, focusing on populations typically excluded from randomized trials. The analysis synthesized observational evidence to determine whether baseline disability modifies key outcomes after MT. Clinically, the results help refine prognostic counseling and patient selection for MT in real-world patients with pre-existing functional impairment.

Arend RB, Peroni BZ, Kieling DM et al. · The neuroradiology journal · (2026) · View on PubMed ↗

---

Pulmonary Hypertension & Respiratory Critical Care

Treatment Strategies for Achieving and Maintaining Low-Risk Status in Pulmonary Arterial Hypertension: A Systematic Review.

This systematic review evaluated treatment strategies aimed at achieving and maintaining low-risk status in adults with Group 1 pulmonary arterial hypertension (PAH) and linked them to low-risk attainment and long-term outcomes. Across heterogeneous risk tools and study designs, the review synthesized evidence from trials, registries, and cohorts reporting validated risk stratification endpoints. The findings clarify which therapeutic approaches are most consistently associated with low-risk status and improved outcomes in PAH.

Chaoddhary SY, Yatiraju SRK, Chellamani A et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Plasma proteomic analysis identified potential therapeutic targets for pulmonary arterial hypertension.

This iScience study integrated UK Biobank Pharma Proteomics Project plasma proteomics (49,272 participants; 337 incident PAH cases) with drug-target Mendelian randomization to identify proteins associated with incident pulmonary arterial hypertension (PAH). It prioritized 5 candidates for validation in the Sugen5416/hypoxia rat model and confirmed lung tissue changes consistent with human plasma trends for TNFRSF10A upregulation and UMOD downregulation, with in vitro assays showing UMOD treatment attenuated PAH-related cellular phenotypes. The approach identifies druggable protein targets and provides mechanistic leads for developing new PAH therapies.

Hu S, Xie Y, Tan JS et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

β3-Adrenergic Receptor Agonism Reduces Right Ventricular Systolic Pressure in a Preclinical Model of Heart Failure With Preserved Ejection Fraction-Associated Pulmonary Hypertension.

This preclinical study tested whether β3-adrenergic receptor (ADRB3) agonism improves pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF-PH) in male and female AKR/J mice. In a high-fat diet–induced HFpEF-PH model, mice were randomized to mirabegron (low or high dose) or nebivolol, and the key reported outcome was reduced right ventricular systolic pressure with ADRB3 modulation (with an antagonist cohort also included). The work supports ADRB3 agonists—specifically mirabegron—as potential therapeutic candidates for HFpEF-PH where no established treatments exist.

Lteif C, Gawronski BE, Flohr RM et al. · Journal of cardiovascular pharmacology and therapeutics · (2026) · View on PubMed ↗ · Free PDF ↗

Akkermansia muciniphila and Its Extracellular Vesicles Alleviate LPS-Induced Acute Respiratory Distress Syndrome in Rats: Integrated Microbiome, Metabolomic, and Transcriptomic Analyses.

This rat study compared live Akkermansia muciniphila (AKK) versus AKK-derived extracellular vesicles (AKK-EVs) in an LPS-induced acute respiratory distress syndrome (ARDS) model using integrated microbiome, metabolomic, and lung transcriptomic analyses. Both AKK and AKK-EVs alleviated LPS-induced lung injury, with multi-omics evidence supporting immunomodulatory and metabolic mechanisms underlying protection. These results suggest AKK-EVs as a potential therapeutic strategy for ARDS by targeting gut-lung immune-metabolic pathways.

Liao L, Dong B, Zeng W et al. · Journal of inflammation research · (2026) · View on PubMed ↗ · Free PDF ↗

---

Endocrine, Metabolic Syndrome & Obesity/PCOS (including GLP-1)

A microbiome-bile acid axis mediates protection from chronic liver disease in females.

This study combined metabolomics from 9,254 individuals with mechanistic experiments to explain female-associated protection from chronic liver disease (CLD). It identified the bile acid isoursodeoxycholic acid (isoUDCA) as a mediator of hepatoprotection, traced its origin to an estrogen-shaped intestinal bacterial consortium, and showed that isoUDCA promotes nuclear SREBP2 accumulation to upregulate STARD4 and its coupled downstream pathway. The findings are significant because they provide a sex-specific microbiome–bile acid–host transcriptional mechanism that could be leveraged for CLD prevention or therapy.

Li M, Kuang J, Chen T et al. · Cell · (2026) · View on PubMed ↗

Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.

This short-term cost-effectiveness analysis evaluated subcutaneous tirzepatide, semaglutide, and liraglutide for adults with overweight or obesity without diabetes in Iran using a decision-tree model over 68 weeks. The study compared payer-perspective clinical effectiveness, adverse events, and treatment discontinuation to estimate relative cost-effectiveness among BMI-defined populations (BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities). These findings are significant for health-system resource allocation by informing which GLP-1/dual GLP-1–GIP option provides the best value for non-diabetic obesity management.

Reiszadeh N, Radmanesh R, Heshmat R et al. · Journal of diabetes and metabolic disorders · (2026) · View on PubMed ↗

Proprotein Convertase Subtilisin/Kexin Type 9: From Biology to Therapeutic Targeting in Cardiovascular Disease.

This narrative review synthesized evidence on proprotein convertase subtilisin/kexin type 9 (PCSK9) biology and its therapeutic targeting across cardiovascular disease. It summarizes PCSK9’s canonical role in LDL receptor (LDLR) degradation and its pleiotropic effects on multiple lipoproteins and organ systems, integrating experimental, translational, and clinical findings. The review is significant for guiding future therapeutic strategies that extend beyond LDLR regulation to broader cardiovascular and metabolic benefits.

Rizzo R, Daraban BS, Tudorache IF et al. · European journal of clinical investigation · (2026) · View on PubMed ↗ · Free PDF ↗

Transient activation of ciliary CCR2 signaling promotes the initiation of adipogenesis.

The study investigated how transient primary cilium assembly and cilium-dependent CCR2 inflammatory signaling regulate adipogenesis in preadipocytes using in vitro and in vivo models. It found that adipose stem cells transiently activate a ciliary gene program to form ciliated preadipocytes that commit to adipogenesis, with CCR2 localizing to primary cilia and high-fat diet remodeling of this ciliary inflammatory signaling. These findings provide a mechanistic link between inflammatory ciliary signaling (CCR2) and the initiation of adipose development relevant to obesity biology.

Wu Y, Kong Y, Li W et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Relationship between Vitamin D Status and the Risk of Obesity without Diagnosed Metabolic Syndrome: A Meta-Analysis of Observational Studies.

The meta-analysis studied the relationship between vitamin D status (including serum/plasma 25-hydroxyvitamin D) and the risk of obesity without diagnosed metabolic syndrome using observational studies. Across 74 studies (110,838 individuals), it pooled estimates and performed subgroup analyses by age, vitamin D detection method, and obesity grade to evaluate whether vitamin D is associated with “healthy obesity.” The results inform whether vitamin D status could be a modifiable risk factor for obesity phenotypes that lack metabolic syndrome.

Liang Y, Luo X, Jiang X et al. · Journal of obesity & metabolic syndrome · (2026) · View on PubMed ↗ · Free PDF ↗

The effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials.

This systematic review and meta-analysis of randomized trials compared glucagon-like peptide-1 receptor agonist (GLP-1RA)-based therapy (alone or with metformin) versus metformin monotherapy in women with polycystic ovary syndrome (PCOS) to assess pregnancy outcomes. The key finding was that GLP-1RA-based regimens improved pregnancy rates relative to metformin alone. These results support GLP-1RA-based metabolic therapy as a potentially more effective strategy for PCOS-related infertility, warranting consideration in reproductive-metabolic treatment planning.

Kar E, Yeh J, Efe MA et al. · European journal of obstetrics, gynecology, and reproductive biology · (2026) · View on PubMed ↗

Targeting the Gut Microbiota-Metabolism Axis: Novel Pharmacological Mechanisms and Translational Application Strategies for Oral Antidiabetic Drugs.

This medicinal review synthesized evidence on how the gut microbiota–metabolism axis influences the pharmacological mechanisms and variable efficacy of oral antidiabetic drugs in type 2 diabetes mellitus (T2DM). It found that differences in gut microbiota composition and metabolic function can modulate drug responses, contributing to inter-individual heterogeneity in glycemic efficacy. The translational implication is that microbiota-targeted strategies (e.g., profiling or modulation) could improve personalization and effectiveness of oral antidiabetic therapy.

Yang R, Zhang S, Fu Z et al. · Medicinal research reviews · (2026) · View on PubMed ↗

Sequential TPRX1 and HERVL activation delineates a progression toward the totipotent-like state.

This study used a dual-reporter human pluripotent stem cell (hPSC) model (TPRX1-EGFP/HERVL-tdTomato) with single-cell transcriptomics and time-resolved flow cytometry to define the sequence of events during 8-cell-like cell (8CLC) induction toward a totipotent-like state. It found that TPRX1 activation precedes the emergence of TPRX1+HERVL+ cells, which transcriptionally most closely resemble in vivo 8-cell embryos. Scientifically, this provides a stepwise regulatory framework for totipotency-like identity acquisition and zygotic genome activation (ZGA) dynamics.

Huang A, Jiang N, Luo S et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

Hepatocyte CBX2 Safeguards Hepatic Lipid Homeostasis by Elevating Ca2+-CaMKK2-AMPK Signaling to Counter MASLD.

This study examined the role of the chromatin regulator Chromobox 2 (CBX2) in hepatocytes for metabolic dysfunction-associated steatotic liver disease (MASLD) using patient samples, multiple mouse models (db/db, ob/ob, HFD, HFHC), and hepatocyte-focused functional experiments. It found that hepatocyte CBX2 expression is reduced in MASLD and that hepatocyte-specific CBX2 overexpression improves steatosis, glucose metabolism, and inflammation, whereas CBX2 deficiency worsens metabolic dysfunction through a Ca2+-CaMKK2-AMPK signaling pathway. The work identifies CBX2 as a potential therapeutic target to restore hepatic lipid homeostasis in MASLD.

Wei X, Lin L, Wang X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Energy-Based Devices for GLP-1 Receptor Agonist-Associated Facial Aging: A Tissue-Specific Safety Framework.

This review examined the proposed phenomenon of GLP-1 receptor agonist–associated facial accelerated aging (“Ozempic face”) and evaluated the safety considerations for using energy-based devices (EBDs) in this context. It characterizes the phenotype as primarily facial volume loss and skin laxity and outlines a tissue-specific safety framework for EBD treatment despite incomplete mechanistic characterization of underlying dermal-adipose and fibroblast changes. Scientifically, it provides a structured approach to mitigate risk while clinicians consider device-based interventions for GLP-1RA-associated facial changes.

Cho CH, Koo S, Yoo K · Clinical, cosmetic and investigational dermatology · (2026) · View on PubMed ↗ · Free PDF ↗

Use of an AI metabolomics score to predict cardiovascular risk among patients with Psoriasis in the MGB and UK Biobanks.

This study used plasma metabolomic profiling and an AI-driven metabolomic risk score (MetaPsoAI) to predict incident cardiovascular events in 1086 individuals with psoriasis from the MGB and UK Biobanks. The key finding was that an AI metabolomics score improved cardiovascular risk prediction beyond traditional clinical predictors and was externally validated. This supports metabolomics-based, disease-specific risk stratification for psoriasis patients to better target preventive cardiovascular care.

Kotanidis CP, Schuermans A, Choksi P et al. · American journal of preventive cardiology · (2027) · 1 citations · View on PubMed ↗ · Free PDF ↗

---

Inflammation, Autoimmunity & Immunometabolism (IBD, RA, ITP, ANCA GN, Psoriasis, HAE)

Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies.

This review article summarizes emerging immune-based therapies for rheumatoid arthritis, focusing on CAR T-cell approaches and bispecific antibodies for patients with persistent inflammatory disease despite standard disease-modifying antirheumatic drugs. It highlights that deep B-cell–depleting strategies and T-cell–engaging therapies aim to eradicate or reprogram pathogenic immune memory, potentially enabling more durable outcomes than continuous immunomodulation. Clinically, it frames how these next-generation biologics could expand options for refractory RA and guide future trial design and treatment positioning.

Avouac J, Jouret M, Bitoun S et al. · The Lancet. Rheumatology · (2026) · View on PubMed ↗

Psoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents.

This narrative review addressed how to choose systemic therapy for psoriasis by matching treatment to patient comorbidities and preferred systemic agents, emphasizing considerations such as inflammatory comorbidities and history of malignancy. It synthesizes evidence to support individualized selection of systemic treatments based on comorbidity profiles, disease extent, prior responses, and patient preferences. The clinical significance is improved, comorbidity-aware prescribing to optimize benefit-risk decisions in psoriasis patients.

Pasumarthi A, Karpoff K, Lebwohl M · Journal of the American Academy of Dermatology · (2026) · View on PubMed ↗

Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD.

This initiative updated the STRIDE-III recommendations for inflammatory bowel disease (Crohn’s disease and ulcerative colitis) by integrating post-STRIDE-II evidence with patient-centered outcomes. The authors used systematic literature searches (MEDLINE, Embase, Cochrane CENTRAL), surveys of IOIBD members and pediatric gastroenterologists, and a modified Delphi consensus process to define updated treatment targets. Scientifically and clinically, STRIDE-III provides standardized goals for treat-to-target management to improve outcomes across adult and pediatric IBD care.

Turner D, Ricciuto A, Yuval Bar-Asher S et al. · The lancet. Gastroenterology & hepatology · (2026) · View on PubMed ↗

The pyrin inflammasome senses OCTN2-mediated uptake of extracellular ʟ-carnitine from muscle injury or ingestion.

This study examined how the pyrin inflammasome senses OCTN2-mediated uptake of extracellular L-carnitine in LPS-challenged mice and LPS-primed murine and human macrophages. It found that extracellular L-carnitine represses mevalonate synthesis and triggers pyrin inflammasome activation downstream of cellular import via the high-affinity transporter OCTN2. These mechanistic insights connect dietary or injury-derived L-carnitine to inflammasome-driven inflammation and identify OCTN2–mevalonate–pyrin signaling as a potential therapeutic axis.

Elliott EI, Yoshida TM, Nakandakari SCBR et al. · Cell · (2026) · View on PubMed ↗

Epitope-diverse autoantibodies induce neutrophil-epithelial niches driving kidney injury in ANCA-associated glomerulonephritis.

This study examined how epitope-diverse autoantibodies drive kidney injury in myeloperoxidase (MPO)-ANCA-associated glomerulonephritis using single-cell-resolved spatial transcriptomics of treatment-naïve patient biopsies. It identified spatially organized neutrophil–epithelial niches containing HAVCR1+ injured proximal tubular epithelial cells, neutrophils, lymphocytes, and TREM2+ macrophages, with injured epithelial cells expressing chemokines such as CXCL6 and CXCL16. These findings clarify a mechanistic immune microenvironment for ANCA-mediated injury and suggest niche-targeted interventions to mitigate renal damage.

Nishide M, Matsushita H, Mizuno Y et al. · The Journal of experimental medicine · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Bispecific antibodies targeting TL1A and IL-12/23p40 suppress pathogenic Th1/Th17 responses and ameliorate colitis in mice.

This preclinical study engineered bispecific antibodies (KA-4316 and half-life–extended KA-5817) that co-target TL1A and IL-12/23p40, and tested their effects on pathogenic Th1/Th17 responses and colitis in mice. The bispecifics suppressed TL1A–DR3 and IL-12/23p40–IL-12Rβ1 signaling and ameliorated colitis compared with single-target approaches, with KA-5817 designed for improved FcRn binding via YTE mutations. The work suggests a dual TL1A/IL-12/23p40 therapeutic strategy that could improve efficacy over monotherapies for inflammatory bowel disease.

Li X, Peng H, Hao F et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

Comparative Efficacy and Safety of Bruton Tyrosine Kinase and Spleen Tyrosine Kinase Inhibitors in Immune Thrombocytopenia: A Network Meta-Analysis of Clinical Trials.

This network meta-analysis compared Bruton tyrosine kinase (BTK) inhibitors (rilzabrutinib) and spleen tyrosine kinase (SYK) inhibitors (HMPL-523/sovleplenib and fostamatinib) for primary immune thrombocytopenia (ITP) using five clinical trials totaling 660 patients. Across comparisons versus placebo, the analysis found statistically and clinically improved platelet response (≥50×10^9/L) with these kinase inhibitors and characterized their adverse-event profiles. The results help clinicians rank BTK versus SYK inhibitor options for primary ITP based on comparative efficacy and safety evidence.

Abulehia A, Alshareef RB, Khateeb S et al. · EJHaem · (2026) · View on PubMed ↗ · Free PDF ↗

Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies.

This article reviewed long-term prophylaxis strategies for hereditary angioedema (HAE) and specifically addressed clinical decision-making when switching between therapies. It highlights that the treatment landscape has expanded with newly approved long-term prophylactic options, including garadacimab and donidalorsen (approved in 2025), making therapy switching increasingly common. The review is clinically significant because it frames how to navigate evolving prophylactic regimens to reduce attack frequency and severity while maintaining patient safety and quality of life.

Banerji A, Bernstein JA, Bouillet L et al. · The World Allergy Organization journal · (2026) · View on PubMed ↗ · Free PDF ↗

Investigation of Clinical and Immunological Features of Alopecia Areata With Comorbid Atopic Dermatitis.

This retrospective study characterized clinical and immunological features of alopecia areata with comorbid atopic dermatitis (AA-AD) compared with non-atopic alopecia areata and atopic dermatitis-only groups. Using flow cytometry on peripheral blood mononuclear cells (PBMCs), multiplex cytokine assays, and immunofluorescence on scalp tissue from 123 AA-AD patients, 119 non-atopic AA patients, and 126 AD patients (2011–2024), the authors identified distinct age/severity patterns and immune differences associated with AA-AD. These findings are significant because they improve phenotyping of AA-AD and may guide more tailored immunologic evaluation and treatment strategies.

Yan X, Xie X, Gao X et al. · Allergy · (2026) · View on PubMed ↗

Pain Management Strategies for Older Adults in Palliative Care: A Scoping Review.

This scoping review mapped evidence on pain management strategies for older adults receiving palliative care, classifying interventions into opioid analgesics, non-opioid medications, procedural, non-pharmacological, educational, and multifaceted approaches. It summarized the nature and extent of the available studies and how frequently different strategy types were reported for this population. The review identifies gaps and supports evidence-informed selection of pain interventions tailored to older patients in palliative settings.

Bérubé M, Linsotan S, Gauthier L et al. · Ageing research reviews · (2026) · View on PubMed ↗ · Free PDF ↗

HECTD1 Directs HIF-1α to Facilitate Intestinal Inflammation and Carcinogenesis via Promoting Th17 Differentiation and Glycolysis.

This study explored how the E3 ligase HECTD1 regulates Th17 cell metabolism and fate by directing HIF-1α, using mechanistic assays and T-cell-specific HECTD1 deletion in murine models of inflammatory bowel disease (IBD) and colitis-associated cancer (CAC). It found that HECTD1 promotes IGF2BP3-dependent HIF-1α translation to drive Th17 glycolysis and differentiation, and that T-cell-specific loss of HECTD1 reduces colitis severity and CAC. The findings suggest that targeting the HECTD1–IGF2BP3–HIF-1α metabolic axis could be a strategy to treat IBD and prevent CAC.

Xu S, Han Q, Wang F et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Blockade of EP3 attenuates cardiac fibrosis by suppressing TGF-β1-Smad2/3 signaling through the Smurf2-mediated Smad7 ubiquitination.

This preclinical study tested whether blocking the EP3 prostaglandin E2 receptor attenuates cardiac fibrosis induced by isoproterenol in global EP3 knockout mice (EP3−/−) and cardiac fibroblast–specific EP3 knockout models. EP3 blockade reduced fibrosis by suppressing the TGF-β1–Smad2/3 pathway through Smurf2-mediated Smad7 ubiquitination. Scientifically, it identifies an EP3–Smurf2–Smad7 regulatory axis as a mechanistic target for antifibrotic therapy.

Ye L, Xu H, Tang H et al. · Military Medical Research · (2026) · View on PubMed ↗ · Free PDF ↗

Future Treatments for Tobacco Dependence.

This narrative review synthesized evidence on pharmacologic and counseling-based interventions for tobacco dependence, focusing on nicotine replacement therapy (NRT), bupropion, varenicline, and cytisinicline (cytisine). It concluded that combined psychological counseling plus medication is the most effective approach and outlined research opportunities, particularly optimizing cytisinicline dosing and evaluating its effectiveness/safety in smokers with chronic disorders and at higher doses versus varenicline. The review guides future clinical trial design to improve smoking cessation outcomes and expand evidence for cytisinicline use.

Jimenez-Ruiz CA, Cristóbal Fernández MI, de Granda-Orive JI et al. · Open respiratory archives · (2027) · View on PubMed ↗ · Free PDF ↗

Panax notoginseng Saponins Accelerate Diabetic Wound Repair by Minimizing Mitochondrial Dysfunction and Inhibiting Pyroptosis of Macrophage via Regulating Ephx2/11,12-EET Axis.

This mouse and macrophage study tested whether Panax notoginseng saponins (PNS) accelerate streptozotocin-induced diabetic wound repair by modulating mitochondrial dysfunction and pyroptosis, focusing on the Ephx2/11,12-EET axis. PNS dose-dependently improved wound closure, collagen deposition, and metabolic parameters in diabetic mice and inhibited macrophage pyroptosis while reducing mitochondrial dysfunction, mechanistically implicating regulation of Ephx2/11,12-EET signaling. These findings support PNS as a candidate pro-healing therapy for diabetic wounds targeting inflammatory cell death pathways.

Chen N, Zhu B, Sun CH et al. · Food science & nutrition · (2026) · View on PubMed ↗ · Free PDF ↗

---

Epigenetic/Genetic Regulation in Development, Aging & Reproduction

Fertility, pregnancy, and women’s health in bronchiectasis: a multicenter study and ELF-EMBARC patient survey.

This multicenter retrospective cohort study and patient survey examined fertility characteristics, pregnancy outcomes, and reproductive health experiences in women with bronchiectasis across EMBARC-affiliated centers (pregnancies 2012–2023). It collected clinical, pulmonary, obstetric, and neonatal data and paired them with an international patient-reported survey to characterize reproductive outcomes and disease-related influences. The findings are significant for counseling women of reproductive age with bronchiectasis and for informing clinical management during fertility and pregnancy.

Boehm-Cohen L, Pollock J, Kompatsiari E et al. · Chest · (2026) · View on PubMed ↗

SIRT6 Activation Improves Intervertebral Disc Health in the Aging Spine.

This study tested whether systemic activation of the NAD+-dependent deacetylase SIRT6 using the small-molecule agonist MDL-800 improves intervertebral disc health in aging mice. MDL-800 treatment improved disc morphology and cell viability and reduced degeneration scores, alongside decreased H3K9 acetylation and reduced senescence and inflammatory markers (including p21, IL-6, TGF-β, and CCL2). These results support SIRT6 activation as a mechanistically grounded therapeutic strategy to slow age-related intervertebral disc degeneration.

Ramteke P, Watson B, Jagannath S et al. · Aging cell · (2026) · View on PubMed ↗

Declining centromere strength compromises meiotic chromosome segregation in aging oocytes.

This study investigated how aging affects meiotic chromosome segregation in mouse oocytes by examining centromere structure and function. It found reduced levels of centromeric CENP-A and CENP-C in aged oocytes, and acute CENP-A degradation during meiosis I destabilized CENP-C and increased segregation errors even in young oocytes. The work links declining centromere strength to aneuploidy risk in aging, identifying CENP-A/CENP-C maintenance as a potential target to preserve oocyte fidelity.

Lemonnier T, Dumont M, Leem J et al. · The Journal of cell biology · (2026) · View on PubMed ↗ · Free PDF ↗

Hypomagnesemia in Hypoparathyroidism, Sensorineural Deafness, and Renal Dysplasia Syndrome Caused by Pathogenic Variants of GATA3.

This retrospective clinical study examined the prevalence and mechanisms of hypomagnesemia in patients with hypoparathyroidism, sensorineural deafness, and renal dysplasia (HDR/Barakat syndrome) caused by pathogenic GATA3 variants. Among 66 European patients, the authors assessed magnesium-balance abnormalities and used GATA3 chromatin immunoprecipitation (ChIP) sequencing to identify how GATA3 regulates genes relevant to magnesium homeostasis. The results clarify a previously underrecognized electrolyte complication of GATA3-driven disease and provide mechanistic leads for managing hypomagnesemia in HDR syndrome.

Kahlman EJEM, van der Zanden N, Zaťková E et al. · Kidney international reports · (2026) · View on PubMed ↗ · Free PDF ↗

Reduced insulin/IGF-1 signaling extends reproductive span through somatic gonadal collagen-mediated maintenance of oocyte and embryo quality in Caenorhabditis elegans.

This work studied whether reduced insulin/IGF-1 signaling (rIIS) preserves reproductive function in Caenorhabditis elegans by maintaining somatic gonadal collagen structures that support oocyte and embryo quality. In daf-2(e1370) worms, IIS reduction extended reproductive span and maintained oocyte morphology and reduced embryonic abnormalities through somatic gonadal collagen-mediated support. The results connect endocrine longevity pathways to tissue-level extracellular matrix maintenance, suggesting conserved mechanisms for reproductive aging.

Kaushik N, Rastogi S, Jain V et al. · Cell communication and signaling : CCS · (2026) · View on PubMed ↗ · Free PDF ↗

Systemic Loss of Chromosome Y Associates With Age-Related Ophthalmic Diseases in Middle-Aged Men: A Longitudinal Multi-Omic Study.

This longitudinal multi-omic study analyzed 223,051 middle-aged men from the UK Biobank to determine how mosaic loss of chromosome Y (LOY) in hematopoietic cells relates to age-related ophthalmic disease risk. Systemic LOY uniquely and independently predicted a higher incidence of age-related macular degeneration (AMD), with a reported hazard ratio indicating increased risk over a long preclinical window. The findings support LOY as a measurable biomarker for future AMD risk and provide a mechanistic link between hematopoietic aging and sensory organ degeneration.

Chen T, Xiang Z, Zhang Z et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Lipid requirements for brain development and function: what we can learn from Drosophila melanogaster.

This review examined how lipid metabolism supports brain development and function in Drosophila melanogaster, focusing on neuroblasts, neurons, and glia. It found that lipids are required for neuroblast proliferation and fate decisions, neuronal “fueling,” and glia-mediated processes such as phagocytosis, with multiple lipid profiling approaches enabling mechanistic study. The work highlights conserved lipid-dependent pathways that may inform understanding and treatment of neurodevelopmental disorders linked to impaired lipid metabolism.

He K, Dee MM, Simmonds AJ · Genome · (2026) · View on PubMed ↗

Acinar-Derived Organoids Reveal Stage-Specific Control of Acinar Plasticity.

This study used single acinar cell–derived pancreatic organoids to test whether adult acinar-lineage cells retain redifferentiation capacity after metaplastic expansion and to define signals required at each transition. It found that stage-specific culture conditions allow expanded acinar-lineage organoids to reacquire acinar features, with epidermal growth factor (EGF)/EGFR signaling initiating conversion from a maintained state. These findings provide mechanistic guidance for controlling acinar plasticity ex vivo, with implications for understanding injury-driven regeneration and oncogenic progression.

Hou Y, Li S, Li C et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Mechanobiology & Cell Cycle/Genome Maintenance

mechanoLight: A genetically encoded fluorescent biosensor for visualizing 5-HT2AR mechanotransduction in live cells.

This work developed mechanoLight, a genetically encoded red fluorescent biosensor engineered into the third intracellular loop of the serotonin 5-HT2A receptor (5-HT2AR) to visualize receptor mechanotransduction in live cells. The biosensor selectively reported 5-HT2AR conformational changes in response to fluid shear stress with minimal sensitivity to 5-HT, enabling direct imaging of mechanical activation. This provides a tool to dissect how GPCRs convert mechanical cues into biochemical signaling, advancing mechanobiology and potential therapeutic targeting of 5-HT2AR pathways.

Baek IY, Kim H, Kwon D et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

Identification and functional analysis of sRNAs in Pseudomonas aeruginosa quorum sensing and virulence regulation.

This study used a combined computational-experimental pipeline to identify and functionally characterize small RNAs (sRNAs) in Pseudomonas aeruginosa PAO1, generating a pan-sRNome across 484 strains. It defined 1663 sRNAs and characterized nine newly discovered sRNAs (including PA0982.1) as core or accessory elements within quorum sensing and virulence regulatory networks, with PA0982.1 acting as a direct regulator in the rhl quorum sensing pathway. The work expands the regulatory map of bacterial sRNAs and provides candidate sRNA targets for controlling quorum sensing and virulence.

Li T, Lu B, Chen F et al. · Genes & diseases · (2027) · View on PubMed ↗ · Free PDF ↗

Stk1 is required for BlaR1-mediated broad-spectrum β-lactam resistance in epidemic-causing strains of Staphylococcus aureus.

This study investigated the role of the serine-threonine kinase Stk1 in BlaR1-mediated broad-spectrum β-lactam resistance in epidemic-causing Staphylococcus aureus strains. It showed that Stk1 phosphorylation of BlaR1 stabilizes BlaR1’s membrane-spanning state and retention, enabling proper β-lactam sensing and downstream mecA induction that drives resistance. The work implies that targeting Stk1 could potentiate β-lactam efficacy against MRSA by interfering with the BlaR1→mecA signaling pathway.

Poon R, Satishkumar N, Mosimann WA et al. · Nature communications · (2026) · View on PubMed ↗

Structure based discovery of antipsychotic-like TAAR1 agonists.

This study used structure-based virtual screening and experimental testing to discover antipsychotic-like agonists of trace amine-associated receptor 1 (TAAR1). By docking 65 million molecules to the active state of TAAR1 and testing 55 top candidates, the authors identified 14 TAAR1 agonists with mid-nanomolar to micromolar potencies and high functional selectivity. These results provide lead compounds and a discovery pipeline for developing TAAR1-targeted therapeutics with potentially improved side-effect profiles.

Huang S, Liu H, Wu Y et al. · Nature communications · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Three-dimensional chromatin architecture is rapidly restored after DNA replication.

This study examined how three-dimensional chromatin architecture changes immediately after DNA replication in human cells, focusing on chromatin-bound factors and looping proteins. It found that transcription factors and looping proteins rapidly associate with nascent DNA, with CTCF and YY1 binding immediately after replication and chromatin loops (39–425 kb) re-form within ~10 minutes. The results indicate that chromatin 3D structure is only briefly disrupted during replication, informing models of how transcriptional programs are maintained post-replication.

Fenstermaker TK, Petruk S, Mazo A · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Arthroscopic-Assisted Lower Trapezius Transfer Improves Outcomes in Patients With Irreparable Posterosuperior Rotator Cuff Tears Irrespective of the Presence of External Rotation Lag Sign.

This retrospective cohort study evaluated arthroscopic-assisted lower trapezius transfer in patients with irreparable posterosuperior rotator cuff tears, stratifying outcomes by presence or absence of a preoperative external rotation (ER) lag sign. The key finding was that arthroscopic-assisted lower trapezius transfer improved clinical outcomes similarly regardless of whether the ER lag sign was present preoperatively, with postoperative functional recovery tracking over time in both groups. Clinically, this suggests surgeons can counsel patients that an ER lag sign does not preclude benefit from the procedure.

Hachem AI, Marcet P, Ezzeddine H et al. · Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association · (2026) · View on PubMed ↗

Management of acute infusion-related reactions in AAV gene therapy guided by mechanistic insight.

This report analyzed management of acute infusion-related reactions (IRRs) in AAV gene therapy using mechanistic insight, describing IRRs observed in participants receiving AAV8 (DTX401 for glycogen storage disease type Ia) and AAV9 (UX701 for Wilson’s disease). The IRRs occurred during/within six hours of infusion and were associated with rapid infusion rates despite premedication with antipyretics and antihistamines in later cases. The clinical significance is improved IRR prevention/management strategies for safer administration of AAV gene therapies.

Sullivan BA, Collis R, Cahayag R et al. · Molecular therapy. Advances · (2026) · View on PubMed ↗ · Free PDF ↗

Massive histone H3 phosphorylation without mitotic chromosome condensation.

This mechanistic cell biology study investigated how histone H3 phosphorylation relates to mitotic chromosome condensation by using a CDK1as chemical-genetic system to accumulate cells in G2 and manipulating CDK1 activity with inhibitors and phosphatase inhibition (calyculin A). It showed that massive histone H3 phosphorylation can occur without mitotic chromosome condensation, indicating that phosphorylation alone is not sufficient to drive chromatin compaction during mitosis. The results refine models of mitotic chromatin regulation and clarify which molecular events are necessary versus merely correlated with chromosome condensation.

Ustun I, Borsò M, Kochanova NY et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on October 20, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.